It has been suggested that anti-sclerostin medications could be developed for use in jawbone-related conditions, as regulating alveolar bone turnover may offer a therapeutic approach for managing periodontal disease and facilitating orthodontic treatment [34]. The gene discussed is SOST; the disease is periodontal disorder.